Meeting
2013 Genitourinary Cancers Symposium
Genetic polymorphisms and sunitinib outcome in metastatic renal-cell carcinoma: A prospective observational study and validation.
Authors
Carlos A. Farfán
Uro-Oncology Unit, 12 de Octubre Universitary Hospital, Madrid, Spain
Carlos A. Farfán , Daniel E. Castellano , Cristina Rodriguez-Antona , Julio Benitez , Guillermo De Velasco , Felipe Villacampa , Federico de la Rosa , Eva Andres , Juan Manuel Sepúlveda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 403)
DOI
10.1200/jco.2013.31.6_suppl.403
Abstract #
403
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.
First Author: Sergio Bracarda
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless
Poster
2023 ASCO Genitourinary Cancers Symposium
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9).
First Author: Umberto Basso
Poster
2022 ASCO Genitourinary Cancers Symposium
A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Manish Kohli